SLC2A1 and amyotrophic lateral sclerosis: Our proteomics approach has identified other possible transporters that could be further investigated to provide a more detailed characterization of the BBB, which might highlight in addition to Glut1, other transporters that could be exploited for enhancing CNS drug delivery in ALS.